Core Points - The company has established a system to manage the shares held by its directors and senior management, ensuring compliance with relevant laws and regulations [1][2][3] - Directors and senior management must notify the board secretary of their trading plans before buying or selling shares, and any transactions must be disclosed within two trading days [3][4] - There are specific restrictions on the transfer of shares by directors and senior management, including a limit of 25% of their total shares per year and a prohibition on trading during certain periods [5][6][7] Summary by Sections - **Management of Shareholding**: The system aims to clarify procedures for managing shares held by directors and senior management, including those held in others' accounts [1][2] - **Trading Regulations**: Directors and senior management are required to be aware of laws against insider trading and must adhere to commitments regarding their shareholding [2][3] - **Disclosure Requirements**: Any changes in shareholding must be reported to the board and disclosed on the stock exchange within specified timeframes [3][4] - **Transfer Limitations**: There are restrictions on the percentage of shares that can be transferred annually, with specific conditions for different scenarios [4][5] - **Prohibition Periods**: Certain periods are designated during which directors and senior management cannot trade shares, including before financial reports and during investigations [6][7] - **Consequences of Non-compliance**: Violations of these regulations may result in the company retaining any profits from illegal trades and potential administrative penalties for the individuals involved [7][8]

Core Viewpoint - The document outlines the information disclosure regulations for Jiangsu Kangwei Century Biotechnology Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of the company and its investors [1][2][3]. Group 1: General Provisions - The company must comply with various laws and regulations, including the Company Law and Securities Law, to ensure proper information disclosure [1]. - Information disclosure is defined as the act of publicly announcing significant information that could impact stock prices, in accordance with regulatory standards [3]. - The company and its information disclosure obligors must ensure that disclosed information is truthful, accurate, complete, and easily understandable [2][4]. Group 2: Information Disclosure Obligations - The company must disclose all information that could significantly affect stock prices or investment decisions, including major events and financial performance [9][10]. - Information disclosure must be conducted fairly, ensuring all investors have equal access to information without any selective disclosure [2][4]. - The company is required to report any major events that may not meet the legal disclosure standards but could still impact stock prices [4][9]. Group 3: Reporting Procedures - The company must follow a structured process for drafting, reviewing, and disclosing periodic reports, which include quarterly, semi-annual, and annual reports [13][14]. - Major events must be disclosed immediately, detailing the cause, current status, and potential impact on the company [28]. - The board of directors is responsible for ensuring that all disclosures are accurate and timely, with specific roles assigned to the board secretary and other management personnel [22][23]. Group 4: Internal Reporting and Compliance - The company has established internal reporting mechanisms to ensure that all significant information is communicated to the board in a timely manner [39][40]. - Directors and senior management are responsible for monitoring and reporting any significant changes in the company's operations or financial status [61][62]. - The company must maintain confidentiality regarding undisclosed information and ensure that all personnel comply with these confidentiality requirements [76][77].

General Overview - The document outlines the information disclosure management system for Jiangsu Kangwei Century Biotechnology Co., Ltd, focusing on the procedures for deferring and exempting information disclosure obligations [2][3]. Information Disclosure Deferral and Exemption - The company can defer or exempt information disclosure without applying to the Shanghai Stock Exchange if the information falls under specific conditions outlined in the listing rules [3]. - Information that involves trade secrets or confidential business information can be deferred or exempted if it meets certain criteria, such as potential harm to the company or others if disclosed [3][4]. Criteria for Deferral and Exemption - The criteria for deferring or exempting disclosure include: 1. Disclosure of core technology information that may lead to unfair competition. 2. Disclosure of operational information that could infringe on the commercial secrets of the company or third parties. 3. Other situations where disclosure could severely harm the interests of the company or others [3][4]. Responsibilities and Procedures - The company must maintain strict confidentiality regarding state secrets and cannot use the excuse of confidentiality to promote business [3][4]. - A mechanism for accountability is established for any failure to report deferral or exemption matters in a timely manner, with potential penalties for responsible individuals [4][5]. Documentation and Record-Keeping - The company is required to keep detailed records of any deferral or exemption actions, including the reasons and internal review processes, for a minimum of ten years [4][5]. - Specific forms and documentation are outlined for the approval process of deferring or exempting disclosures, including a confidentiality commitment from individuals aware of the information [5][8].

江苏康为世纪生物科技股份有限公司 第一章 总则 第三章 薪酬标准和支付方式 第七条 公司董事的薪酬构成： （一） 非独立董事 内部董事根据其在公司担任的具体职务领取相应的岗位薪酬。公司 内部董事同时在公司兼任高级管理人员，其薪酬标准和绩效考核依 据高级管理人员薪酬与考核办法执行。外部董事在公司领取外部董 事津贴，公司外部董事津贴按月发放，除此以外不再另行发放薪酬。 任职津贴数额可由董事会建议调整，报股东会通过。 （二） 独立董事 在公司领取独立董事津贴，公司独立董事津贴按月发放，除此以外 不再另行发放薪酬。独立董事出席公司董事会、股东会和专门委员 会等会议及按照相关法律、法规和《公司章程》的规定行使其他法 定职权产生的必要费用由公司承担。 第一条 为进一步规范江苏康为世纪生物科技股份有限公司（以下简称"公司"）董 事、高级管理人员的薪酬管理，建立科学有效的激励与约束机制，保证公司 董事有效地履行其职责和义务，有效调动公司高级管理人员的工作积极性， 提高公司的经营管理效率，进一步促进公司稳定持续发展，根据《中华人民 共和国公司法》《上海证券交易所科创板股票上市规则》及《江苏康为世纪 生物科技股份有限公司章程》（ ...

证券代码：688426 证券简称：康为世纪 公告编号：2025-025 江苏康为世纪生物科技股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏康为世纪生物科技股份有限公司(下称"公司")第二届董事会第十六次会议于 王春香主持，公司全体监事和高级管理人员列席了本次会议。 本次会议的召集、召开符合《中华人民共和国公司法》等法律法规以及《公司章程》 的相关规定，会议决议合法、有效。 一、审议通过《关于<2025 年半年度报告>及其摘要的议案》 董事会认为：公司《2025 年半年度报告》及其摘要的编制和审议程序符合相关法律 法规及《公司章程》等内部规章制度的规定，内容与格式符合《公开发行证券的公司信 息披露内容与格式准则第 3 号—半年度报告的内容与格式（2021 年修订）》、《公开发行 证券的公司信息披露编报规则第 15 号——财务报告的一般规定（2023 年修订）》等有关 文件的要求，真实、准确、完整地反映了公司 2025 年半年度财务状况和经营成果等事 项，不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果： ...

Core Points - The company held its second special meeting of the independent directors on August 27, 2025, with all three independent directors present [1] - The meeting was conducted in accordance with relevant laws and regulations, including the Company Law and the Management Measures for Independent Directors of Listed Companies [1] - The independent directors reviewed and approved the proposal regarding the expected daily related transactions for the year 2025, confirming that the decision-making process was legal and effective [1] Summary of Related Sections - The expected daily related transactions for 2025 are necessary for the company's normal business operations and are based on the inherent connections between the company's business and that of related parties [1] - The related transactions are conducted under principles of fairness, justice, and reasonableness, ensuring that the pricing is fair and does not harm the interests of the company or its shareholders, particularly minority shareholders [1] - The voting results for the proposal were unanimous, with all three independent directors voting in favor [2]

证券日报网讯 8月28日晚间，康为世纪发布公告称，公司第二届监事会第十四次会议审议通过了《关于 及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

格隆汇8月28日丨康为世纪(688426.SH)发布中报，2025上半年实现营业总收入8711.87万元，同比增长 29.74%；归属母公司股东净利润-5591.11万元，较上年同期亏损增加585.43万元；基本每股收益为-0.51 元。 ...

证券日报网讯 8月28日晚间，康为世纪发布公告称，公司第二届董事会第十六次会议审议通过了《关于 及其摘要的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯8月28日晚间，康为世纪发布公告称，同意补选职工代表董事殷剑峰先生为公司第二届董 事会审计委员会委员。 ...